150 related articles for article (PubMed ID: 25531722)
1. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
O'Kane GM; Lyons TG; Colleran GC; Ahmad MW; Alken S; Kavanagh EC; Fitzpatrick D; Murray B; Kelly CM
Oncol Res Treat; 2014; 37(12):757-60. PubMed ID: 25531722
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab-induced colitis on FDG PET/CT.
Lyall A; Vargas HA; Carvajal RD; Ulaner G
Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
5. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Lipson EJ; Bodell MA; Kraus ES; Sharfman WH
J Clin Oncol; 2014 Jul; 32(19):e69-71. PubMed ID: 24493726
[No Abstract] [Full Text] [Related]
6. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
Raad RA; Pavlick A; Kannan R; Friedman KP
Clin Nucl Med; 2015 Mar; 40(3):258-9. PubMed ID: 25290291
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.
Bacanovic S; Burger IA; Stolzmann P; Hafner J; Huellner MW
Clin Nucl Med; 2015 Nov; 40(11):e518-9. PubMed ID: 26164177
[TBL] [Abstract][Full Text] [Related]
10. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
11. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
12. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
14. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.
Barina AR; Bashir MR; Howard BA; Hanks BA; Salama AK; Jaffe TA
Abdom Radiol (NY); 2016 Feb; 41(2):207-14. PubMed ID: 26867901
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Orbitopathy Associated With Ipilimumab.
Sheldon CA; Kharlip J; Tamhankar MA
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S155-S158. PubMed ID: 26068559
[TBL] [Abstract][Full Text] [Related]
16. Primary malignant melanoma of the lung: a case report and review of the literature.
Kundranda MN; Clark CT; Chaudhry AA; Chan V; Daw HA
Clin Lung Cancer; 2006 Jan; 7(4):279-81. PubMed ID: 16512984
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
18. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
20. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
